Beneficial effect of post-procedural abciximab in patients undergoing primary coronary angioplasty and presenting with the no-reflow phenomenon

Acute Cardiac Care

Volumn 10, Issue 2, 2008, Pages 100-103

  Picchi, Andrea ^a   Zacà, Valerio ^a   Focardi, Marta ^a   Fineschi, Massimo ^a   Sinicropi, Giuseppe ^a   Casini, Stefano ^a   Buti, Alberto ^a   Pierli, Carlo ^a   Mondillo, Sergio ^a   Marzilli, Mario ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Acute myocardial infarction; Glycoprotein IIb IIIa receptor antagonists; Ischemia reperfusion injury; Percutaneous coronary interventions

Indexed keywords

ABCIXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REPERFUSION INJURY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 45849099069     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.1080/17482940701639401     Document Type: Article

References (22)

1. Kloner RA, Ganote CE, Jenning RB. The 'no-reflow' phenomenon after temporary coronary occlusion in dogs. J Clin Invest. 1974;54:1496-508.
2. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol. 1993;21:537-45.
3. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105:656-62.
4. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, et al. Clinical implications of the 'no-reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93:223-8.
5. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, et al. Angiographic no-reflow phenomenon as a predictor of adverse long term outcome in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 2000;36:1202-9.
6. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. 1997;30:1193-9.
7. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv. 2002;57:444-51.
8. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effect of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000;101:2154-9.
9. Limbruno U, Micheli A, De Carlo M, Amoroso G, Rossini R, Palagi C, et al. Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion. Circulation. 2003;108:171-6.
10. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, et al. TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. Circulation. 1999;99:2720-32.
11. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary artery stents in acute myocardial infarction. Circulation. 1998;98:2695-701.
12. Petronio AS, Rovai D, Musumeci G, Baglini R, Nardi C, Limbruno U, et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute myocardial infarction treated by primary coronary angioplasty. Eur Heart J. 2003;24:67-76.
13. van't Hof AWJ, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade: Zwolle Myocardial Infarction Study Group. Circulation. 1998;97:2302-6.
14. Gibson MC, Schomig A. Coronary and myocardial angiography. Angiographic assessment of both epicardial and myocardial perfusion. Circulation. 2004;109:3096-105.
15. Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. Rescue' utilization of abciximab for the dissolution of thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol. 1997;30:1729-34.
16. Marzilli M, Sambuceti G, Testa R, Fedele S. Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina. J Am Coll Cardiol. 2002;40:2102-9.
17. Sezer M, Oflaz H, Gören T, Okçular I, Umman B, Nişanci Y, et al. Intracoronary streptokinase after primary percutaneous intervention. N Engl J Med. 2007;356:1823-34.
18. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomized, placebo controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) investigators. Circulation. 1998;98:734-41.
19. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. ADMIRAL investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-903.
20. de Queiroz Fernandes Araujo JO, Veloso HH, Braga De Paiva JM, Filho MW, Vincenzo De Paola AA. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trial. Am Heart J. 2004;148:937-43.
21. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, et al. Abciximab as adjuncitve therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293:1759-65.
22. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004;292:362-6.